Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

The Impact of Post-Transplant Cyclophosphamide (PTCy) with or without MMF in the Prevention of De Novo and Progressive / Relapsing Chronic Graft-Versus-Host Disease after HLA-Matched Donor Transplant

Rima M. Saliba, Curtis Marcoux, Amin Alousi, Gabriela Rondon, Julianne Chen, May Daher, MD, Richard E. Champlin, Katayoun Rezvani, Elizabeth J. Shpall, Rohtesh S. Mehta

Blood (2023) 142 (Supplement 1): 2188.

https://doi.org/10.1182/blood-2023-188108

Published: 2023

Journal Articles

Phase 2 Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Wei-Ying Jen, Courtney D. DiNardo, Kelly S. Chien, Yesid Alvarado-Valero, Lucia Masarova, Mark Brandt, Debra Bull-Linderman, Naval Daver, Guillermo Montalban-Bravo, Alex Bataller, Guillermo Garcia-Manero, Ghayas C. Issa, Amin Alousi, Nicholas J. Short, Farhad Ravandi, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4273.

https://doi.org/10.1182/blood-2023-182969

Published: 2023

Journal Articles

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Blood (2023) 142 (Supplement 1): 1.

https://doi.org/10.1182/blood-2023-186963

Published: 2023

Journal Articles

Tagraxofusp Maintenance Post-Hematopoietic Stem Cell Transplantation Provides Long-Term Survival and Manageable Safety for a Patient with Blastic Plasmacytoid Dendritic Cell Neoplasm

Qaiser Bashir, Marina Y. Konopleva, Glorette Abueg, Jeremy Ramdial, Chitra Hosing, Samer A. Srour, Amin Alousi, Uday R. Popat, Yago Nieto, Gheath Alatrash, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Naveen Pemmaraju

Blood (2023) 142 (Supplement 1): 7058.

https://doi.org/10.1182/blood-2023-178874

Published: 2023

Journal Articles

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Blood (2023) 142 (Supplement 1): 897.

https://doi.org/10.1182/blood-2023-187859

Published: 2023

Journal Articles

Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis

Jayastu Senapati, Sanam Loghavi, Patrick K Reville, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Elias Jabbour, Nicholas J. Short, Naveen Pemmaraju, Abhishek Maiti, Ghayas C. Issa, Uday R. Popat, Amin Alousi, Elizabeth J. Shpall, Koji Sasaki, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2023-179380

Published: 2023

Journal Articles

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Blood (2023) 142 (Supplement 1): 475.

https://doi.org/10.1182/blood-2023-188032

Published: 2023

Journal Articles

Incidence and Risk Factors of Veno-Occlusive Disease Are Different in Younger Versus Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 4920.

https://doi.org/10.1182/blood-2023-185025

Published: 2023

Journal Articles

Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results

Blood (2023) 142 (Supplement 1): 774.

https://doi.org/10.1182/blood-2023-172980

Published: 2023

Journal Articles

Allogeneic Transplant for CLL Richter's Transformation: Single Center Retrospective Analysis

Alejandro Marinos Velarde, Rima M. Saliba, Celina Ledesma, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Uday R. Popat, Qaiser Bashir, Yago Nieto, David Marin, Betul Oran, Amanda L. Olson, Samer A. Srour, Amin Alousi, Jeremy Ramdial, Partow Kebriaei, Alessandra Ferrajoli, William G. Wierda, Richard E. Champlin, Chitra Hosing

Blood (2023) 142 (Supplement 1): 7086.

https://doi.org/10.1182/blood-2023-173194

Published: 2023

Journal Articles

Effective treatment of low-risk acute GVHD with itacitinib monotherapy

Blood (2023) 141 (5): 481–489.

https://doi.org/10.1182/blood.2022017442

Published: 2023

Includes: Supplemental data

Journal Articles

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

Blood (2022) 139 (12): 1908–1919.

https://doi.org/10.1182/blood.2021013290

Published: 2022

Includes: Supplemental data

Journal Articles

Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?

Stefan O. Ciurea, Piyanuch Kongtim, Ankur Varma, Gabriela Rondon, Julianne Chen, Samer Srour, Qaiser Bashir, Amin Alousi, Rohtesh Mehta, Betul Oran, Uday Popat, Chitra Hosing, Amanda Olson, Naval Daver, Marina Konopleva, Richard E. Champlin

Blood (2020) 135 (6): 449–452.

https://doi.org/10.1182/blood.2019003662

Published: 2020

Includes: Supplemental data

Journal Articles

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion

Blood (2018) 131 (11): 1248–1257.

https://doi.org/10.1182/blood-2017-07-798751

Published: 2018

Includes: Supplemental data

Journal Articles

Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas

Yago Nieto, MD PhD, Peter F Thall, Benigno C Valdez, PhD, Junsheng Ma, MS, Melissa Timmons, Michelle Trapp, Sairah Ahmed, MD, Elizabeth J Shpall, MD, Roy B Jones, MDPhD, Chitra Hosing, MD, Paolo Anderlini, Uday Popat, MD, Muzaffar H. Qazilbash, MD, Amin Alousi, MD, Alison M Gulbis, PharmD, Celina Ledesma, Richard E. Champlin, MD, Borje S Andersson, MDPhD

Blood (2017) 130 (Supplement 1): 1966.

https://doi.org/10.1182/blood.V130.Suppl_1.1966.1966

Published: 2017

Journal Articles

Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation

Blood (2017) 129 (22): 3031–3033.

https://doi.org/10.1182/blood-2017-02-766154

Published: 2017

Includes: Supplemental data

Journal Articles

Additional Consolidation after Attaining Second Complete Remission Results in Superior Outcomes after Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 4680.

https://doi.org/10.1182/blood.V128.22.4680.4680

Published: 2016

Journal Articles

Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning in Older Patients with Myelodysplastic Syndromes

Orhan Kemal Yucel, MD, Rima M Saliba, PhD, Gabriela Rondon, MD, Sairah Ahmed, MD, Amin Alousi, MD, Qaiser Bashir, MD, Stefan O. Ciurea, MD, Uday R. Popat, MD, David Marin, MD, Katy Rezvani, MD PhD, Partow Kebriaei, MD, Elizabeth J. Shpall, MD, Richard E. Champlin, MD, Betul Oran, MD

Blood (2016) 128 (22): 5847.

https://doi.org/10.1182/blood.V128.22.5847.5847

Published: 2016

Journal Articles

Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation

Blood (2016) 128 (2): 297–312.

https://doi.org/10.1182/blood-2016-03-706317

Published: 2016

Includes: Supplemental data

Journal Articles

Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19 + Malignancies

Blood (2015) 126 (23): 862.

https://doi.org/10.1182/blood.V126.23.862.862

Published: 2015

NARROW

The Impact of Post-Transplant Cyclophosphamide (PTCy) with or without MMF in the Prevention of De Novo and Progressive / Relapsing Chronic Graft-Versus-Host Disease after HLA-Matched Donor Transplant

Phase 2 Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Tagraxofusp Maintenance Post-Hematopoietic Stem Cell Transplantation Provides Long-Term Survival and Manageable Safety for a Patient with Blastic Plasmacytoid Dendritic Cell Neoplasm

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Incidence and Risk Factors of Veno-Occlusive Disease Are Different in Younger Versus Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results

Allogeneic Transplant for CLL Richter's Transformation: Single Center Retrospective Analysis

Effective treatment of low-risk acute GVHD with itacitinib monotherapy

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion

Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas

Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation

Additional Consolidation after Attaining Second Complete Remission Results in Superior Outcomes after Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia

Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning in Older Patients with Myelodysplastic Syndromes

Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation

Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19 + Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only